Home › Research › Russian bioregulator peptides

Evidence teardown · Vilon · Vesugen · Cartalax · Bronchogen · Peptides · Healthy aging · Updated October 28, 2026

Published October 28, 2026 · Updated October 28, 2026

Vilon, Vesugen, Cartalax and Bronchogen: what the evidence on Russian “bioregulator” peptides shows

Short Russian peptides sold as “bioregulators” are having a moment on X. One October 23 post about taking “Russian peptides (pinealon, epitalon, vilon)” for deep sleep drew about 241,600 views.[1] Four of the names now circulating, vilon, vesugen, cartalax and bronchogen, are two- to four-amino-acid peptides developed in St Petersburg since the 1990s.[2][3] We sorted all 97 relevant PubMed records for the four names. Our plain answer: the research program is long and consistent, but almost all of it is cell, tissue or animal work. We found 8 small studies that gave vilon or vesugen to people, none of them describing a placebo group in its abstract. We found none for cartalax or bronchogen, and no registered trial of any of the four.[24][23]

Why this matters now

Mentions of these peptides, plus “Khavinson” and “bioregulator,” ran at 57 to 98 English-language X posts a day from October 22 to 27, 2026, rising to 98 on October 27.[1] Popular posts make claims about sleep, energy and aging, and some tell readers to start “cycles” of several peptides at once. This page does not repeat schedules or sellers. Instead, it traces the claims back to the original papers and patents, which are mostly in Russian journals and rarely summarized in English.[1][24] For epitalon and pinealon, see our epitalon and pinealon teardown.

What the four peptides are

All four come from the same research group, led by Vladimir Khavinson, which sees short peptides as signals that switch genes on or off in specific tissues. The group’s 2021 systematic review lists these effects for each one:[3]

The roots of the program are in thymus extracts. A 1997 review by Vladimir Morozov and Khavinson describes Thymalin, a calf-thymus extract used in Russia, and Thymogen, a synthetic dipeptide based on a molecule isolated from it. It then introduces vilon as “a novel immunomodulatory dipeptide.”[2] A 2022 paper from the group lists Thymogen as a “medicinal product,” while Russian studies describe vesugen and similar peptides as “cytogens” used in “preventive medical nutrition.”[4][15]

What the human studies show

The 8 studies we found that gave these peptides to people were all published in one Russian-language journal, Advances in Gerontology. In our reading of the abstracts, all were small and none describes a placebo group or blinding:[24]

• Vilon in elderly patients with colorectal cancer (2005): described as “pioneer experience” with “preliminary results.” The abstract gives no patient numbers.[9]
• Vilon in type 1 diabetes (2006, 2007): reported improvements in blood-clotting measures when vilon was added to usual treatment. PubMed tags the 2006 paper as a randomized trial, but its abstract does not describe how.[10][11]
• Vesugen for erectile dysfunction (2014): 41 men with vessel-related ED, comparing penile blood flow before and after treatment, with no control group described.[12]
• Vesugen and pinealon for “biological age” (2015, 2016): 32 people aged 41 to 83, and 110 people in a comparison with carbon dioxide baths, hyperbaric oxygen and massage.[13][14]
• Vesugen and pinealon in workers (2012, 2015): truck drivers and other workers exposed to occupational hazards.[16][15]

Most of these studies measured blood markers, blood flow, questionnaires or “biological age” scores. The colorectal cancer report mentions 2-year survival, but its abstract gives no figures. None of the abstracts reports hard outcomes such as heart attacks, disease or death from a placebo-controlled design.[13][14][12]

The animal and lab record

Most of the evidence is from rodents and cells. A 2000 study reported that vilon injected under the skin of female mice from 6 months of age “prolonged the lifespan, and prevented the development of spontaneous neoplasms.” It had no effect on “free radical processes.”[7] A 2010 review by two lead researchers of the program says long-term treatment with “some peptide preparations” increased mean lifespan by 20 to 40% in rodents.[8] For bronchogen, the main in-body studies are in rat models of obstructive lung disease.[20]

The proposed mechanism is that these peptides enter cell nuclei and bind DNA. A 2011 study showed fluorescent-labeled versions of related short peptides (epitalon, pinealon and testagen) inside the nuclei of HeLa cells, and test-tube assays suggested bronchogen binds certain DNA sequences.[18] A Tbilisi State University group reported that vilon loosened tightly packed chromatin in lymphocytes from older people, in cells grown in a dish.[19] These are plausible lab findings. They do not show that the same thing happens in a person who takes the peptide.[18][19]

One older paper goes further. It reports a second peak of activity in thymus cells at “super-low doses” of 10^-17 to 10^-15 mol/l and proposes that, at those levels, a signal is passed to cells “without the formation of any ligand-receptor complex,” with the “water medium” given an “active role.”[17] In Jabbit’s arithmetic, 10^-17 mol/l is about 6 million molecules in a liter of fluid. A signal that needs no receptor is not an established mechanism in pharmacology, so we treat this as an unconfirmed hypothesis.[17]

Who did the research

About two-thirds of the relevant records (65 of 97) list Khavinson as an author, and most of the rest come from Russian groups publishing in the same two journals.[24] Some authors of the human studies are also listed as inventors on the patents. For example, G. A. Ryzhak co-authored vilon clinical reports and is named on the vesugen patent.[9][10][6] Inventor-researchers are common in drug development, and this overlap says nothing about whether the results are right. What it does mean is that independent replication matters, and in our search we found little of it in people.[24][23]

Can they work by mouth?

Many posts describe taking these peptides by mouth. The patents describe injection: the vesugen patent says its composition “is intended for parenteral administration,” and the vilon patent lists routes “for example, parenteral, oral, intranasal or local.”[6][5] The group’s own 2022 paper says that taken orally, peptides “must be absorbed into the bloodstream through the intestinal barrier in their active forms,” and that “it is important to study the absorption mechanism.”[4] It reports that the vilon dipeptide was broken down in solutions and partly in tissues. Its case that these peptides can enter cells through transporters rests on computer modeling and literature review, not on blood levels measured in people.[4]

A widely shared X post argued that the gut transporter PEPT1 explains how these peptides work orally.[1] PEPT1 belongs to the transporter family the 2022 paper modeled, so the idea has a basis. But an independent 2009 study of 228 dipeptides in gut-lining cells concluded that their effects in the body are “most likely limited due to the very low intestinal permeability of dipeptides.” That study did not test these peptides specifically.[4][21] We found no published human study measuring how much oral vilon, vesugen, cartalax or bronchogen reaches the blood.[24]

Safety: what is and isn’t known

• The 2000 mouse study reported “no unfavourable effects on animal development” from long-term vilon.[7] Animal data do not establish human safety.
• The 2015 human study of vesugen and pinealon reported “prooxidant activity” and a drop in CD34+ blood stem-cell markers that the authors called “significant inhibition of hemopoiesis.” The authors also reported no change in chromatin packing and called the peptides safe “on nuclear genetic level,” adding: “This property should be studied in future.”[13]
• None of the four is an FDA-approved drug. None appears on FDA’s page of bulk drug substances that may present significant safety risks, which does list epitalon, citing a possible risk of immune reactions.[22] Not being on that page is not a sign of safety. It most likely reflects that no one asked FDA to review them for compounding.
• We found no registered trial and no systematic safety data for any of the four.[23][24] We did not test any product sold online, so we cannot say what those products contain.

What the program gets right

To be fair to the researchers: they have pursued one idea consistently for about three decades, published the mechanisms they propose, patented specific molecules, and in recent years written English-language reviews with international co-authors.[3][4][5][6] Short peptides can be real drugs. Thymogen is a dipeptide that the group describes as a medicinal product, and many approved drugs are peptides.[2][4] The lab findings could be pointers worth testing. In our view, the problem is that they have not been tested in the kind of controlled human trial that would show whether they help.[24][23]

The longevity question

The appeal is clear: a few amino acids that “reset” aging tissues. The strongest support is mouse lifespan data from the same program, and lifespan gains in mice often fail to carry over to people.[7][8] In the human studies, “biological age” was measured with the authors’ own scores, not with outcomes such as frailty, disease or survival.[13][14] In our analysis, these peptides are currently a hypothesis about aging, not a tested intervention.

What a careful reader should notice

• “Decades of Russian research,” as one widely shared post put it, is accurate, but about two-thirds of the records list one author, and most are lab or animal studies.[24]
• No human study we found describes a placebo group in its abstract. Before-and-after studies cannot separate the peptide from placebo effects or time.[12][13][10]
• The patents describe injection. Evidence that oral doses reach the blood is modeling, not measurement.[6][4]
• “Super-low dose” claims rely on a receptor-free signaling hypothesis that has not been confirmed.[17]
• Absence from FDA’s safety-risk list does not mean FDA reviewed these peptides.[22]

FAQ

What are Khavinson peptide bioregulators?

They are short peptides, two to four amino acids long, developed by Vladimir Khavinson’s group in St Petersburg. The group proposes that they regulate genes in specific tissues. Vilon (Lys-Glu), vesugen (Lys-Glu-Asp), cartalax (Ala-Glu-Asp) and bronchogen (Ala-Glu-Asp-Leu) are four of them.[3][2]

Is there human evidence for vesugen?

We found five small Russian studies from 2012 to 2016, including 41 men with erectile dysfunction and 32 people in a “biological age” study. Most combined it with pinealon, and none describes a placebo group in its abstract.[12][13][14][16][15]

Does vilon extend lifespan?

In mice, a 2000 study reported longer lifespan and fewer spontaneous tumors. No human study has tested lifespan, and the three human reports we found covered cancer treatment and diabetes markers.[7][9][10][11]

Is there evidence for cartalax or bronchogen in people?

We found no published human studies and no registered trials. The research is in cells, tissue cultures and rat models.[24][23][20]

Do oral bioregulator peptides get absorbed?

This has not been shown in people. The developers’ own 2022 paper says absorption still needs study and relies on computer modeling, and the patents describe injection.[4][6]

Are these peptides FDA-approved or legal to compound?

None is an FDA-approved drug, and none appears on FDA’s safety-risk page for compounding ingredients as of its April 2026 version. That page lists epitalon. Not being listed is not evidence of safety.[22]

Bottom line

Vilon, vesugen, cartalax and bronchogen come from a long-running Russian research program with patents, mouse lifespan data and many lab studies.[5][6][7][3] What is missing is the step that would show they help people: placebo-controlled trials, independent replication and data on whether oral forms are absorbed.[24][23][4] Until that exists, the viral claims on X go well beyond the evidence.[1][24]

This page analyzes published studies, patents, registry and FDA searches, and counts of public X posts. It is not medical advice and does not recommend any product, dose or schedule. Small uncontrolled studies cannot show that a peptide caused an effect. Quality judgments and cross-study comparisons are Jabbit’s analysis. Charts were rebuilt by Jabbit from the sources cited in each caption.